Kura Oncology (KURA)
(Delayed Data from NSDQ)
$21.76 USD
-0.30 (-1.36%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $21.79 +0.03 (0.14%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Brokerage Reports
Kura Oncology, Inc. [KURA]
Reports for Purchase
Showing records 241 - 258 ( 258 total )
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
2Q18 Results; Tipifarnib Going Pivotal Soon and Heme Program Evolving
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Targets Acquired for Tipifarnib; HRAS and CXCL12 Define Multiple Paths Forward; Initiating Coverage at Buy and $31 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Appreciating the Wider Opportunities for Tipifarnib, and Beyond
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Significant Program Updates Expected in 2H18
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; Positive EoP2 Meeting Provides Clear Path for Tipifarnib
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Improved Response Rate for Tipifarnib in HRAS-Mutant HNSCC
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Kura Oncology, Inc.
Industry: Medical - Biomedical and Genetics
Initiating with an OUTPERFORM and $19 PT: Tip-ping the Balance to Success
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R